



“Achieving the elimination of viral hepatitis within evolving health systems”

TUESDAY 7 JUNE, 2022

| Time | Outline |
|-------------|---|
| 12.00-13.10 | <p>Welcome and high-level panel*</p> <p>Welcome Danjuma Adda, president, World Hepatitis Alliance, Center for Initiative and Development (CFID) and Chagro-Care Trust (CCT), Nigeria</p> <p>Panel moderator: Dr Su Wang, chairperson, World Hepatitis Summit 2022 Programme Committee; past president, World Hepatitis Alliance, USA Dr Meg Doherty, Director HHS, WHO, Switzerland</p> <p>Speakers:</p> <ul style="list-style-type: none"> • Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO) • Ms Helen Clark, Former Prime Minister of New Zealand • Her Excellency Mrs Jeannette Kagame, First lady of Rwanda • Professor Khaled Abdel Ghaffar, Acting Minister of Health and Population, Egypt • Dr Tenu Avafia, Deputy Executive Director, Unitaid • Mr Charles Gore, Executive Director, Medicines Patent Pool |
| 13.10-13.15 | <p>Message from WHA member Alliance Global, Ukraine</p> |
| | <p>New momentum and high impact through the new WHO Global Health Sector Strategy*</p> |



| | |
|--|---|
| | <p>➤ This session will focus on presenting the progress in viral hepatitis elimination and the new WHO Global Health Sector Strategy. Presentations around the different strategic directions will illustrate countries' progress, innovations, community voices and what it will take to reach elimination.</p> <p>Chair:</p> <ul style="list-style-type: none"> • Dr Margaret Hellard, Burnet Institute, Australia <p>Co-Chair:</p> <ul style="list-style-type: none"> • Andy Seale, WHO, Switzerland <p>13.15-13.20 Opening remarks Dr Ren Minghui, WHO, Switzerland</p> <p>13.20-13.35 Introducing the new Global Health Sector Strategy (2022-2030) and the implication for countries <i>Dr Meg Doherty, WHO, Switzerland</i></p> <p>13.35-14.25 Panel discussion: Championing the global strategy in different contexts</p> <p>Making giant progress toward elimination <i>Dr Mohamed Hassany, Ministry of Health, Egypt</i></p> <p>Leveraging the systems approach in optimizing universal health coverage (UHC) for viral hepatitis elimination in India <i>Dr Sandhya Kabra, Ministry of Health, India</i></p> <p>Accelerating hepatitis elimination in Nigeria <i>Dr Sule Abdullahi, Executive Governor, Nasarawa state, Nigeria</i></p> <p>Innovations that are needed to reach hepatitis elimination <i>Dr John Ward, Coalition for Global Hepatitis Elimination, USA</i></p> <p>Viral hepatitis, the global community and people living with hepatitis (PLWVH)</p> |
|--|---|



| | |
|--------------------|---|
| <p>14.25-14.35</p> | <p><i>Rachel Halford, Hepatitis C Trust, UK</i></p> <p>Q&A</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Funmi Lesi, WHO, Switzerland • Niklas Luhmann, WHO, Switzerland <p>Viral Hepatitis elimination: Report of piloting validation criteria in 7 countries <i>Dr Funmi Lesi, WHO, Switzerland</i></p> |
| <p>14.35-15.05</p> | <p>Roundtable discussion: Measuring progress towards 2030 validation Implications from WHO Piloting countries</p> <p>Representatives from:</p> <p>Egypt / Thailand / Brazil / Rwanda / Georgia / England / Mongolia</p> <p>Preview of Upcoming HCV guidance <i>Dr Philippa Easterbrook, WHO, Switzerland</i></p> |
| <p>15.05-15.15</p> | <p>Closing remarks <i>Dr Ren Minghui, WHO, Switzerland</i></p> |
| <p>15.30-15.35</p> | <p>Lightning talks: Oral abstracts of distinction—<i>Advocacy, awareness and education efforts*</i></p> <p>Chair: Helen Tyrrell, World Hepatitis Alliance, skills-based board member, Australia (TBC)</p> <p>Welcome</p> |
| <p>15.35-15.40</p> | <p>A global open call for enhancing viral hepatitis public engagement and advocacy <i>Dr Tiange Philip Zhang, Loyola University Medical Center, USA</i></p> |



| | |
|-------------|---|
| 15.40-15.45 | <p>Have a heart, save my liver! Which countries restrict treatment? <i>Joelle Dountio Ofimboudem, TAG, USA</i></p> |
| 15.45-15.50 | <p>Activities to raise awareness of hepatitis patients in terms of labor law and health law <i>Dr Hilal-Unalmis Duda, Turkish Liver Foundation, Turkey</i></p> |
| 15.50-15.55 | <p>Advocacy is a powerful tool to ensure hepatitis C healthcare for people who use drugs: The Moroccan experience <i>Dr Taha Brahni, Association De Lutte Contre Le Sida (ALCS), Morocco</i></p> |
| 15.55-16.00 | <p>Nurses as viral hepatitis advocates: Empowerment through education <i>Dr Aayushi Rastogi, India</i></p> |
| 16.00-16.30 | <p>Discussion and Q&A</p> |
| | <p>Hepatitis-free generation: Preventing mother-to-child transmission (PMTCT) *</p> <ul style="list-style-type: none"> ➤ This session will focus on describing the global burden of mother-to-child transmission (MTCT) of hepatitis B and gaps in antenatal screening, treatment and infant vaccination ➤ Global birth dose coverage and implementation challenges to birth dose will be addressed in different settings ➤ The experience of mothers living with viral hepatitis and the challenges they face in accessing services for themselves and their infants will be recognised <p>Chairs:</p> <ul style="list-style-type: none"> • Lien Tran, The Peter Doherty Institute for Infection and Immunity; World Hepatitis Alliance, WPRO Board Member • Dr Morkor Newman, WHO, Switzerland |
| 16.30-16.37 | <p>Welcome and introduction to GVAC</p> |
| 16.37-16.44 | <p>The urgency and necessity of PMTCT in achieving hepatitis elimination <i>Dr Funmi Lesi, WHO, Switzerland</i></p> |
| 16.44-16.51 | <p>Médecins Sans Frontières' PMTCT work In Mozambique</p> |



| | |
|-------------|--|
| | <i>Kwalila Roberto Tibana, Médecins Sans Frontières</i> |
| 16.51-16.58 | CDA analysis of birth dose coverage in Gavi vs non Gavi countries <i>Devin Razavi-Shearer, Center for Disease Analysis Foundation, USA</i> |
| 16.58-17.03 | Birth dose vaccine coverage and barriers to timely uptake in Nasarawa And Kano States, Nigeria <i>Chukwuemeka Agwuocha, CHAI, Nigeria</i> |
| 17.03-17.08 | How mothers with chronic hepatitis B understand and experience PMTCT interventions in Victoria, Australia <i>Nafisa Yussf, The Doherty Institute, Australia</i> |
| 17.08-17.13 | Familial clustering of hepatitis C in the Pakistani population <i>Professor Yasir Waheed, Foundation University Islamabad, Pakistan</i> |
| 17.13-17.18 | PMTCT and hepatitis B vaccination of children in Bangladesh (including Rohingya refugees) <i>Professor Mohammad Ali, National Liver Foundation of Bangladesh, Bangladesh</i> |
| 17.18-17.30 | Q&A and closing remarks |
| | <p>From policy to people: Bringing services closer to communities</p> <ul style="list-style-type: none"> ➤ This session will focus on examining collaborations across sectors which effectively translate policies to programs for communities ➤ Various multi-stakeholder initiatives that are improving access to services such as testing and care for people living with viral hepatitis will be explored <p>Co-Chairs:</p> <ul style="list-style-type: none"> ● Rachel Halford, Hepatitis C Trust; World Hepatitis Alliance, EURO board member, UK ● Marie-Emmanuelle L. Zouré, Ministry of Health, Burkina Fasso |
| 16.30-16.40 | Welcome and opening remarks |
| 16.40-16.45 | Community values and preferences for hepatitis C testing and treatment |



| | |
|-------------|--|
| | <p><i>Rosemary Delabre, Coalition Plus, France</i></p> |
| 16.45-16.52 | <p>Cross-sector partnerships to eliminate hepatitis B inequities in the USA <i>Catherine Freeland, Hepatitis B Foundation, USA</i></p> |
| 16.52-16.59 | <p>A community-led hepatitis B and C care model, including same-day hepatitis C “test and treat” <i>Nalinkanta Rajkumar, Community Network for Empowerment, India</i></p> |
| 16.59-17.06 | <p>Nurse-led hepatitis C testing and treatment in a rural setting in Battambang province, Cambodia <i>Dr Daniel O’Keefe and Suna Balkan</i></p> |
| 17.06-17.13 | <p>Hepatitis C micro-elimination among underserved communities of Islamabad, federal capital of Pakistan <i>Dr Huma Qureshi, Integral Global, Pakistan</i></p> |
| 17.13-17.20 | <p>Community leadership mobilising Australia to achieve its national hepatitis C treatment target <i>Amanda Bode and Carrie Fowlie, Hepatitis Australia, Australia</i></p> |
| 17.20-17.30 | <p>Q&A and closing remarks</p> |
| | <p>Leave no one behind</p> <ul style="list-style-type: none"> ➤ This session will focus on exploring the issues which lead to health inequality in term of viral hepatitis ➤ Best practice on how to meet the needs of highly affected groups that are underserved by health systems will be discussed ➤ Community perspectives regarding viral hepatitis will be shared <p>Co-Chairs</p> <ul style="list-style-type: none"> ● Niklas Luhmann, WHO, Switzerland ● Javier Hourcade Bellocq, Communities Delegation to the Global Fund, Argentina |
| 16.30-16.40 | <p>Welcome and opening remarks</p> |
| 16.40-16.47 | <p>How Colombia is working to develop a hepatitis response including the most vulnerable populations</p> |



| | |
|--|---|
| <p>16.47-16.54</p> <p>16.54-17.01</p> <p>17.01-17.08</p> <p>17.08-17.15</p> <p>17.15-17.30</p> | <p><i>Dr Cielo Yaneth Ríos Hincapié, Ministry of Health, Columbia</i></p> <p>Seroprevalence of hepatitis B in pregnant Syrian refugees <i>Dr Sukran Kose, Izmir University of Health Sciences, Tepecik Training and Research Hospital, Turkey (TBC)</i></p> <p>Hepatitis A, B and C seroprevalence in the vulnerable Quilombola population from northeast Brazil <i>Livia Melo Villar, Fiocruz, Brazil</i></p> <p>Epidemiological trends of hepatitis B and C in Lahore Pakistani for MSM population <i>Syed Raza Haider Tirmizi, Dostana Male Health Society, Pakistan</i></p> <p>Pilot project - HDV: An awareness campaign with the Mongolian community in Germany <i>Achim Kautz, Kautz5 Gug, Germany</i></p> <p>Q&A and closing remarks</p> |
| <p>17.30-18.30</p> | <p>Symposium</p> <p>The impact of stigma and discrimination affecting people living with hepatitis B</p> <p>Brought to you by: Janssen</p> <p>Moderator: James Merson, Global Therapeutic Area Head, Infectious Diseases, Janssen</p> <p>Panelists:</p> <ul style="list-style-type: none"> • Lien Tran, The Peter Doherty Institute for Infection and Immunity; World Hepatitis Alliance, WPRO Board Member • Dr Robert Gish, M.D., Clinical Professor, University of California, Skaggs School of Pharmacy and Pharmaceutical Sciences, USA • Professor Jeff Lazarus, Barcelona Institute for Global Health (ISGLOBAL), Spain |



| | |
|-------------|--|
| | <ul style="list-style-type: none">• Jason Crum, patient advocate |
| 18.30-19.30 | World Hepatitis Alliance 15th Anniversary Party |



WEDNESDAY 8 JUNE, 2022

| Time | Outline |
|-------------|--|
| 13.00-14.30 | <p>A whole system approach to hepatitis elimination*</p> <ul style="list-style-type: none"> ➤ This session will focus on accelerating progress through collaboration, integration and cooperation with related conditions and across health systems in the pursuit of health for all <p>Chair Cary James, World Hepatitis Alliance, UK</p> <p>Panelists:</p> <ul style="list-style-type: none"> ➤ Dr Juan Castelli, Ministry of Health, Argentina ➤ Luís Mendão, GAT, Portugal ➤ Dr Cary Adams, UICC, Switzerland ➤ Dorothy Mbori-Ngacha, UNICEF, USA ➤ Oanh Khuat, Center for Supporting Community Development Initiatives, Vietnam ➤ Javier Hourcade Bellocq, Communities Delegation to the Global Fund, Argentina |
| 14.30-15.30 | <p>Hepatitis and liver cancer: Gaps and opportunities</p> <ul style="list-style-type: none"> ➤ Leveraging links with liver cancer, including cancer prevention efforts, to help drive hepatitis elimination ➤ Addressing gaps in global liver cancer surveillance in people living with viral hepatitis and the role of innovative diagnostics and treatments <p>Chairs:</p> <ul style="list-style-type: none"> • Maria Buti, EASL, Spain • Gamal Shiha, Egyptian Liver Research Institute and Hospital (ELRIAH); World Hepatitis Alliance, EMRO Board Member |
| 14.30-14.35 | <p>Welcome and opening remarks</p> |



| | |
|-------------|--|
| 14.35-14.42 | <p>Personal story <i>Ibrahima Gueye, Safara Hepatitis, Senegal</i></p> |
| 14.42-14.49 | <p>Hepatitis and liver cancer control: The urgency of implementing what we know <i>Prof Lewis Roberts, Mayo Clinic, USA</i></p> |
| 14.49-14.56 | <p>Viral hepatitis and liver cancer awareness month <i>Luciana Holtz, Oncoguia Cancer organisation in Brazil</i></p> |
| 14.56-15.03 | <p>Liver cancer, viral hepatitis and other major risk factors: A review of the Western Pacific region <i>Dr Eleonora Feletto, The University of Sydney And Cancer Council NSW, Australia</i></p> |
| 15.03-15.10 | <p>How a white paper on liver cancer can contribute to hepatitis elimination <i>Marko Korenjak, ELPA, Slovenia</i></p> |
| 15.10-15.17 | <p>Changing viral etiology of hepatocellular carcinoma in Taiwan, China **** <i>Wan-Long Chuang</i></p> |
| 15.17-15.30 | <p>Q&A and closing remarks</p> |
| 14.30-14.35 | <p>Fighting stigma and discrimination to achieve social and legal justice</p> <ul style="list-style-type: none"> ➤ This session will focus on how the impact of stigma and discrimination on people living with hepatitis (PLVH) around the world, while often overlooked, is a significant barrier to PLVH accessing care. ➤ The serious implications for many dimensions of patients' lives, including their mental health, will be discussed. ➤ How do we capture the experiences of PLVH with regard to stigma and discrimination? ➤ How do we combat stigma and discrimination in order to achieve social and legal justice? <p>Co-Chairs:</p> <ul style="list-style-type: none"> • Professor Carla Treloar, University of New South Wales, Australia • Chris Munoz, Yellow Warriors Society, Philippines <p>Welcome and opening remarks</p> |



| | |
|-------------|--|
| 14.35-14.42 | World Hepatitis Alliance hepatitis B stigma report and hepatitis C stigma survey findings <i>Jessica Hicks, World Hepatitis Alliance, UK</i> |
| 14.42-14.49 | HIV stigma index <i>Caroline Thomas</i> |
| 14.49-14.56 | The global impact of discrimination on people with hepatitis B <i>Catherine Freeland, Hep B Foundation, USA</i> |
| 14.56-15.03 | How stigma and discrimination affecting the elimination of HBV? Findings in 5 Asian countries <i>Dee Lee, Inno Community Development Organisation, China</i> |
| 15.03-15.10 | Stigma associated diagnosis of hepatitis B and depression among patients with chronic hepatitis B <i>Professor Hee-Soon Juon, Thomas Jefferson University, USA</i> |
| 15.10-15.17 | A mixed method study to assess the social challenges experienced by hepatitis B patients (India) <i>Meenakshi Tomar, Institute of Liver and Biliary Sciences, India</i> |
| 15.17-15.30 | Q&A and closing remarks |
| | Hepatitis integration within health systems: Opportunities offered by universal health coverage, primary health care and HIV services* Co-Chairs: <ul style="list-style-type: none"> • Po-Lin Chan, WHO, India • Dr Patricia Vélez Möller, Guatemalan Association of the Liver; World Hepatitis Alliance, PAHO Board Member |
| 14.30-14.37 | Welcome and opening remarks |
| 14.37-14.44 | The Civil Society Engagement Mechanism (CSEM) Universal Health Coverage (UHC) 2030: Introduction to UHC <i>Eliana Monteforte, Global Health Council</i> |



| | |
|-------------|--|
| 14.44-14.51 | <p>Community-based and HIV integrated screening for hepatitis B and C among key populations in Vietnam <i>Dr Vu Ngoc Bao, Path, Vietnam</i></p> |
| 14.51-14.58 | <p>Achieving global hepatitis elimination: A case study of Elohim Foundation/ FHI360 Epic Project in Nigeria <i>Dr Julius Uchechukwu Ibecheole, Elohim Foundation, Nigeria</i></p> |
| 14.58-15.05 | <p>The failure of the Colombian insurance-based health system for hepatitis C elimination in Colombia <i>Dr Francisco Augusto Rossi, IFARMA Foundation, Colombia</i></p> |
| 15.05-15.30 | <p>Q&A and closing remarks</p> |
| | <p>Lightning talks: Oral abstracts of distinction—<i>Prevention and vaccination</i>*</p> <p>Chair: Dr Ahmed Elsharkawy, University of Birmingham, UK</p> |
| 15.30-15.35 | <p>Customized active engagement can increase hepatitis B vaccine adherence in remote tribal communities <i>Dr Partha Sarathi Mukherjee, Liver Foundation, West Bengal, India</i></p> |
| 15.35-15.40 | <p>Advancing health equity in the US by increasing adult hepatitis B vaccination <i>Michaela Jackson, Hepatitis B Foundation, USA</i></p> |
| 15.40-15.45 | <p>A systematic review of effectiveness, immunogenicity and the impact of paediatric hepatitis A vaccines <i>Dr Nick Walsh, Monash University, Australia</i></p> |
| 15.45-16.00 | <p>Q&A and closing remarks</p> |
| 16.00-17.00 | <p>Hepatitis and the sustainable development goals (SDGs) *</p> <ul style="list-style-type: none"> ➤ Beyond SDG 3.3, working together with the wider SDG movement to accelerate hepatitis elimination and improve the lives of our communities <p>Chair:</p> <ul style="list-style-type: none"> • Cary James, World Hepatitis Alliance, UK |



| | |
|--|---|
| | <p>Panelists:</p> <ul style="list-style-type: none"> • Julia Tainijoki Seyer, World Medical Association • Dr Justin Koonin, UHC2030, Australia • Dr José M. Zuniga, IAPAC and Fast-Track Cities Institute, USA • Doug Webb, UNDP, USA • Professor Mohammad Ali, National Liver Foundation of Bangladesh, Bangladesh • Dr Ricardo Baptista Leite, UNITE - Global Parliamentarians Network, Portugal |
| <p>17.00-17.03</p> <p>17.03-17.10</p> <p>17.10-17.17</p> | <p>Bridging gaps in hepatitis B care and treatment: Bringing science and affected communities together*</p> <ul style="list-style-type: none"> ➤ This session will look at recognising gaps in hepatitis B care and treatment between lower, middle- and high-income countries. ➤ We will hear patient experiences in accessing hepatitis B care and treatment around the world. ➤ We will explore how affected communities can intersect with science to improve care with a lookback on the HIV experience. ➤ We will discuss opportunities for guideline adaptability in various settings, patient preferences and values, and the role of simplified and decentralized care to bridge current gaps. <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Su Wang, chairperson, World Hepatitis Summit 2022 Programme Committee; past president, World Hepatitis Alliance, USA • Dr Philippa Easterbrook, WHO, Switzerland <p>Welcome and opening remarks</p> <p>Low income: Gaps in hepatitis B care and treatment in Ethiopia and other countries <i>Dr Hailemichael Desalegn Mekonnen, St. Paul's Hospital Millennium Medical College, Ethiopia</i></p> <p>Middle income: Bridging gaps in hepatitis B care and treatment in China <i>Dr Fuqiang Cui, Peking University, China CDC, WHO, China</i></p> |



| | |
|-------------|---|
| 17.17-17.24 | <p>High income: Hepatitis B care and treatment in the US <i>Dr Norah Terrault, AASLD, University of Southern California College, USA</i></p> |
| 17.24-17.31 | <p>Perspectives of people living with hepatitis B on access to care and treatment <i>Danjuma Adda, World Hepatitis Alliance, Center for Initiative and Development (CFID) and Chagro-Care Trust (CCT), Nigeria</i></p> |
| 17.31-17.41 | <p>TAG: Lookback at HIV treatment evolution and the involvement of people living with HIV <i>Mark Harrington, TAG, USA</i></p> |
| 17.41-18.00 | <p>Q&A and closing remarks</p> |
| | <p>Youth can't wait</p> <ul style="list-style-type: none"> ➤ This session will focus on understanding the experiences and needs of young people living with viral hepatitis, including the medical and psychological impacts of the virus. ➤ We will define ways of empowering young people living with hepatitis to live full and healthy lives and to become advocates for change. ➤ We will focus on bringing the energy and activism of youth into the viral hepatitis elimination movement. <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Tasnia Noor, Bangladesh Medical Students' Society, Bangladesh • Matthew Bonn, Canadian Association of People Who Use Drugs, Canada <p>17.00-17.05 Welcome and my personal story <i>Matthew Bonn, Canadian Association of People Who Use Drugs, Canada</i></p> <p>17.05-17.10 My personal story <i>David Urick, Community Living Network, USA</i></p> <p>17.10-17.17 Perceived supportive care needs of adolescents with chronic hepatitis B in Ghana <i>Charles Ampong Adjei, University of Ghana, Ghana</i></p> |



| | |
|-------------|--|
| 17.17-17.24 | The innovative use of TikTok to increase community engagement on hepatitis awareness <i>Anika Martin, Hawaii Health and Harm Reduction Center, USA</i> |
| 17.24-17.31 | An initiative to incorporate children, adolescents and pregnant people in elimination efforts <i>Ronni Marks, The Hepatitis C Mentor and Support Group, USA</i> |
| 17.31-17.36 | The importance of a youth-centred movement response in the HIV response and lessons for hepatitis <i>Wole Ameyan, WHO, Switzerland</i> |
| 17.36-17.41 | How providers and others can support a hepatitis youth movement <i>Professor Manal El Sayed, Ain Shams University, Egypt</i> |
| 17.41-18.00 | Q&A and closing remarks |
| | <p>Reaching communities that need it most</p> <ul style="list-style-type: none"> ➤ This session will focus on. learning about the public health importance of key populations and viral hepatitis elimination. ➤ Best practices in delivering services to key populations will be showcased. ➤ We will hear community perspectives. <p>Co-Chairs:</p> <ul style="list-style-type: none"> • Andrew Scheibe, TB HIV Care, South Africa • Dr Aninda Rahman, Communicable Disease Control (CDC), Bangladesh (TBC) |
| 17.00-17.07 | Welcome and opening remarks |
| 17.07-17.14 | Going beyond low-hanging fruit: Key population-specific strategies to tackle hepatitis C in Malaysia <i>Dr Muhammad Radzi Abu Hassan, Hospital Sultanah Bahiyah, Malaysia</i> |
| 17.14-17.21 | Reach U: Peer and nursing-led point-of-care hepatitis C testing and treatment combined with outreach work <i>Cristiana Merendeiro, CRESCER - Associação De Intervenção Comunitária, Portugal</i> |



| | |
|-------------|---|
| 17.21-17.28 | <p>Hepatitis C micro-elimination efforts in the prisons of Punjab and Haryana, India <i>Dr Kanudeep Kaur, Find India, India</i></p> |
| 17.28-17.35 | <p>Hepatitis C test and treat roadshow: Reaching homeless communities <i>Philippe Bonnet and Danny Morris, Hepatitis C Trust, UK</i></p> |
| 17.35-17.42 | <p>C-Free: Community-based testing and treatment of hepatitis B and C and HIV in people who use drugs in Thailand <i>Tanyaporn Wansom</i></p> |
| 17.42-18.00 | <p>Q&A and closing remarks</p> |
| 18.00-19.30 | <p>Symposium: Urban HCV Elimination: Lessons from Fast-Track Cities</p> <p>Brought to you by: IAPAC</p> <p>Moderator: José M. Zuniga, IAPAC and Fast-Track Cities Institute</p> <p>Panelists:</p> <ul style="list-style-type: none"> • Leveraging urban hepatitis C elimination for national impact <i>Dr Meg Doherty, WHO, Switzerland</i> • Case Study: Advancing HCV Elimination Goals in Spanish Cities <i>Javier García-Samaniego</i> • Case Study: Progress and Plans for HCV Elimination in Uzbekistan <i>Dr Erkin Musabaev, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Uzbekistan</i> <p>Closing Remarks</p> |



THURSDAY 9 JUNE, 2022

| Time | Outline |
|-------------|---|
| | <p>Viral hepatitis response in the Western Pacific region</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Sahar Bajis, WHO, Manila • Professor Benjamin Cowie, The Peter Doherty Institute for Infection and Immunity, Australia |
| 08.00-08.05 | <p>Welcome and opening remarks Dr Sahar Bajis, WHO, Manila Lien Tran, The Peter Doherty Institute for Infection and Immunity; World Hepatitis Alliance, WPRO Board Member</p> |
| 08.05-08.15 | <p>Learnings from a national implementation <i>Dr Jacqui Richmond, Burnet Institute, Australia</i></p> |
| 08.15-08.30 | <p>Response to the high prevalence of viral hepatitis in Kiribati <i>Dr Thomas Tibwere Russell, Tungaru Central Hospital, Kiribati</i></p> |
| 08.35-08.45 | <p>Bridging the gap <i>Chris Munoz, Yellow Warriors Society of the Philippines, Philippines</i></p> |
| 08.45-09.00 | <p>Progress of triple EMTCT of HIV, syphilis and hepatitis B in China <i>Dr Wang Ai-Ling, National Center for Women and Children's Health, China CDC</i></p> |
| 09.00-09.15 | <p>Malaysia's journey to hepatitis C elimination: From compulsory licensing to treatment decentralization <i>Dr Muhammad Radzi bin Abu Hassan, Ministry of Health Malaysia</i></p> |
| 09.15-09.30 | <p>Successes and challenges with viral hepatitis elimination in Mongolia <i>Dr S Amarzaya, Ministry of Health, Mongolia</i></p> |



| | |
|---|--|
| 09.30-10.00 | <p>Q&A Panel:</p> <ul style="list-style-type: none"> • Dr Wang Ai-Ling, China • Dr Muhammad Radzi bin Abu Hassan, Malaysia • Dr S Amarzay, Mongolia <p>Closing remarks <i>Professor Benjamin Cowie, The Peter Doherty Institute for Infection and Immunity, Australia</i></p> |
| 08.00-08.05 08.05-08.15 08.15-08.55 | <p>Viral hepatitis response in the African region: Promoting hepatitis B PMTCT in Africa and experiences from the first implementers in Africa**</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Casimir Manzenigo, WHO / AFRO • Danjuma Adda, World Hepatitis Alliance, Center for Initiative and Development (CFID) and Chagro-Care Trust (CCT), Nigeria <p>Welcome <i>Dr Benido Impouma, WHO</i></p> <p>Where are we in Africa on the viral hepatitis B PMTCT? <i>Casimir Manzenigo, WHO/AFRO</i></p> <p>Partners panel:</p> <p>How to leverage the progress made in the HIV (and syphilis) elimination pathway <i>Françoise Bigirimana, WHO</i></p> <p>Place of HBV BD in the efforts of the triple elimination of HIV, Syphilis and HBV <i>Julien Kabore, WHO</i></p> <p>HBV PMTCT perspectives from the Africa CDC Viral Hepatitis Prevention and Control Program <i>Bibi Nafiisah Chotun, Africa Centres for Disease Control and Prevention (Africa CDC)</i></p> |



| | |
|--|--|
| <p>08.55-09.35</p> <p>09.35-09.55</p> <p>09.55-10.00</p> | <p>Where are we with the Egyptian initiative in Africa? <i>Mohammed Alborai, Egyptian Initiative, Egypt</i></p> <p>What is and should be the civil society contribution in the HBV PMTCT effort <i>Theobald Owusu-Ansah, Hepatitis Foundation of Ghana, World Hepatitis Alliance, AFRO board member</i></p> <p>Countries panel:</p> <p>Burkina Faso experience: Resources mobilization for HBV PMTCT <i>Marie-Emmanuelle L. Zouré, Ministry of Health, Burkina Fasso</i></p> <p>Sierra Leone experience: Viral hepatitis (B, C) among Ebola survivors and health care workers in Makeni, Sierra Leone <i>Dr Nadège Mafopa Goumkwa, Cameroon</i></p> <p>Botswana experience: as the pioneer of HIV elimination in Africa, what are the lessons can be taken from your experience which can accelerate elimination of HBV? <i>Dr Nkomo, Ministry of Health, Botswana</i></p> <p>Q&A</p> <p>Closing remarks</p> |
| | <p>The viral hepatitis response in the Eastern Mediterranean region</p> <p>Objectives</p> <ul style="list-style-type: none"> ➤ This session will focus on reviewing regional progress and challenges including country examples. ➤ The scaling up of hepatitis B birth dose coverage will be advocated for. <p>Chair:</p> <ul style="list-style-type: none"> • Joumana Hermez, WHO/EMRO • Yvan Hutin, WHO |



| | |
|-------------|---|
| 09:00-09.05 | Welcome and opening remarks |
| 09.05-09.20 | Regional progress of hepatitis elimination in the eastern Mediterranean: Midterm review findings <i>Ahmed Sabry, WHO/EMRO</i> |
| 09.20-09.40 | Sudan costed operational plan and prioritization: Opportunities and challenges of a low-income country <i>Dr Sara Abdallah</i> |
| 09.40-09.50 | Morocco's progress and updated country targets: Refocusing a national response based on epidemiology <i>Dr Ibtissam Khoudri</i> |
| 09.50-10.05 | A public-private partnership for the rapid scale-up of hepatitis testing and treatment <i>Dr Muhammad Ahmar Khan, Association for Social Development, Pakistan</i> |
| 10.05-10.20 | Q&A and discussion |
| 10.20-10.50 | Panel discussion: Hepatitis B elimination—the need for aligned approaches Moderator: Gamal Shiha, Egyptian Liver Research Institute and Hospital (ELRIAH), World Hepatitis Alliance, EMRO Board Member Chairs: <ul style="list-style-type: none"> • Dr Akram Shah, Pakistan (TBC) • Dr Dilawer Noorzai, Afghanistan • Dr Jamila Taiseer Al Abri, Ministry of Health, Oman |
| 10.50-11.15 | Q&A and closing remarks |
| | The viral hepatitis response in the European region |
| 09.30-09.35 | Welcome remarks: <ul style="list-style-type: none"> • Nicole Seguy, WHO/Europe, Denmark |



| | |
|-------------|---|
| 09.35-09.45 | <ul style="list-style-type: none"> • Cary James, World Hepatitis Alliance, UK <p>Meeting objectives and agenda Nicole Seguy, WHO/Europe</p> <p>Session 1: World Hepatitis Summit 2022 abstracts</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Cary James, World Hepatitis Alliance, UK • Marcelo Naveira, WHO/Europe, Denmark |
| 09.45-10.00 | <p>The reality of HCV care in Ireland in 2021: Understanding complex barriers to elimination <i>Nicola Perry and Marcus Keane, The Hepatitis C Partnership, Ireland</i></p> |
| 10.00-10:15 | <p>“ACCESS4ALL”: a holistic intervention for HCV micro-elimination among people in Greek prisons <i>Giannis Petalidis, Hellenic Liver Patients Association "Prometheus", Greece</i></p> |
| | <p>Q&A</p> |
| 10.15-10.30 | <p>Session 2: Good practices and key actions toward elimination</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Rachel Halford, Hepatitis C Trust, World Hepatitis Alliance, EURO board member, UK • Antons Mozalevskis, WHO, Switzerland |
| 10.30-10.45 | <p>A strategic plan for tackling hepatitis C in the Spanish national health system <i>Dr Julia del Amo, Ministry of Health, Spain</i></p> |
| 10.45-11.00 | <p>Uzbekistan Hepatitis Elimination Project (UHEP) <i>Dr Erkin Musabaev, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Uzbekistan</i></p> |
| 11.00-11.15 | <p>Hepatitis B and C prevention, testing and linkage to care for PWID</p> |



| | |
|-------------|---|
| 11.15-11.30 | <p><i>Dr Ketevan Stvilia, National Center for Disease Control (NCDC), Georgia</i></p> <p>Q&A</p> <p>Next steps and closing <i>Nicole Seguy, WHO/Europe, Denmark</i></p> |
| 10.00-10.10 | <p>Viral hepatitis response in the South-East Asian region</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Funmi Lesi, WHO, Switzerland • Dr Bharat Bhushan Rewari, WHO, India <p>Welcome and an overview of the hepatitis situation and regional priorities in South-East Asia <i>Dr Suman Rijal, WHO SEARO</i></p> <p>Country experiences</p> <p>10.10-10.20 Moving ahead on hepatitis agenda in Bangladesh <i>Dr Aninda Rahman, Communicable Disease Control (CDC), Bangladesh (TBC)</i></p> <p>10.20-10.30 Towards an integrated DHIS2 based system for hepatitis B and C monitoring and reporting in Bhutan <i>Lekey Khandu, National HIV/STI/Hepatitis Control Program, Department of Public Health, Ministry of Health, Bhutan (TBC)</i></p> <p>10.30-10.40 Reaching out to grassroots through linkages with primary health care and simplified algorithms – the Delhi experience <i>Dr Ekta Gupta, Institute of Liver and Biliary Sciences, New Delhi, India</i></p> <p>10.40-10.50 Preventing mother to child prevention transmission of hepatitis B – experience from Indonesia <i>Dr Fatchanuralityah, SKM, Viral Hepatitis Programme, Ministry of Health, Jakarta, Indonesia (TBC)</i></p> <p>10.50-11.00 Experiences in testing for hepatitis B and providing hepatitis B vaccination for adult key populations in Timor-Leste</p> |



| | |
|-------------|--|
| | <p><i>Sr Bernardino, National Programme Manager, HIV and Hepatitis, Timor Leste</i></p> |
| 11.00-11.10 | <p>Hepatitis elimination in India: progress and integration, decentralisation to scale up services <i>Dr Sandhya Kabra and Dr Harmeet Singh, National Viral Hepatitis Control programme, India</i></p> <p>Regional updates</p> |
| 11.10-11.20 | <p>Challenges on scaling up hepatitis B birth dose vaccination in the WHO South-East Asia Region <i>Dr Sigrun ROESEL, WHO</i></p> |
| 11.20-11.30 | <p>A regional capacity-strengthening initiative on hepatitis through WHO regional office partnership with Project ECHO <i>Dr Nabeel Mangadan-Konath, WHO</i></p> |
| 11.30-12.00 | <p>Panel discussion and Q&A</p> <p>Role of civil society in accelerating the hepatitis agenda in the Region Moderator: <i>Po-Lin Chan, WHO</i></p> <p>Panelists:</p> <ul style="list-style-type: none"> • Professor RP Shanmugam, Chennai Liver Foundation, World Hepatitis Alliance, SEARO Board Member (India) • Giten Khwairakpam, Treat Asia, Thailand • Han Yang, DNDi • Dr Khin Pyone, Myanmar Liver Foundation (TBC) |
| 12.00-12.10 | <p>Closing remarks <i>Dr Funmi Lesi, WHO, Switzerland</i> <i>Dr Bharat Bhushan Rewari, WHO, India</i></p> |
| 12.00-13.00 | <p>Meet the author I</p> |
| 13.00-14.00 | <p>Meet the author II</p> |



| | |
|-------------|---|
| 13.30-13.32 | <p>Acute viral hepatitis: What is new?</p> <p>Welcome remarks: <i>Rakesh Aggarwal, India</i> <i>Dr Philippa Easterbrook, WHO, Switzerland</i></p> <p>Chairs:</p> <ul style="list-style-type: none"> • Rakesh Aggarwal, India • Dr Philippa Easterbrook, WHO, Switzerland |
| 13.32-14.00 | <p>Hepatitis A: Prevention is now easier – updated WHO SAGE vaccination guidance <i>Dr Christoph Steffen, WHO, Switzerland</i> <i>Rakesh Aggarwal, India</i></p> <p>Q&A</p> |
| 14.00-14.25 | <p>Hepatitis E: Using vaccination to control outbreaks – a new beginning <i>Melanie Marti, WHO, Switzerland, and Andrew Azman, Médecins Sans Frontières</i></p> <p>Q&A</p> |
| 14.25-15.00 | <p>Severe acute non-A-E hepatitis in children in 2021-22 and managing a global response <i>Farah Al-Shorbaji and Dr Philippa Easterbrook, WHO, Switzerland</i></p> |
| 15.00-15.15 | <p>Q&A and panel discussion</p> |
| 15:30-15:40 | <p>The viral hepatitis response in the Region of the Americas***</p> <p>Welcome remarks: <i>Dr Patricia Vélez Möller, Guatemalan Association of the Liver, World Hepatitis Alliance, PAHO Board Member</i> <i>Dr Rubén Mayorga-Sagastume, Pan American Health Organization (PAHO/WHO)</i></p> |



| | |
|-------------|--|
| 15.40-15.50 | <p>An overview of viral hepatitis in the Americas and the role of civil society <i>Dr Patricia Vélez Möller, Guatemalan Association of the Liver, World Hepatitis Alliance, PAHO Board Member</i></p> |
| | <p>Session 1: National Programs Chairs:</p> <ul style="list-style-type: none"> • Dr John Ward, Coalition for Global Hepatitis Elimination, USA • Dr Leandro Sereno, PAHO/WHO, USA |
| 15.50-16.02 | <p>The micro elimination of hepatitis B in Peru <i>Dr Carlos Benites, Ministry of Health, Peru</i></p> |
| 16.02-16.14 | <p>Guyana: Building the national viral hepatitis response and opportunities for integration <i>Hon Dr Frank Anthony, Minister of Health of Guyana</i></p> |
| 16.14-16.26 | <p>Opportunities for subregional cooperation: Viral hepatitis elimination in the Andean Region <i>Dr Paolo Ballardelli, PAHO/WHO Subregional Program for South America</i></p> |
| 16.26-16.38 | <p>Financing the national response to hepatitis C in Mexico <i>Dr Alethse de la Torre Rosas, National Center for the Prevention and Control of HIV / AIDS (CENSIDA), Secretariat of Health, Mexico (TBC)</i></p> |
| 16.38-16.50 | <p>Development of the U.S. viral hepatitis national strategic plan and federal implementation plan 2021 <i>Dr Jessica Deerin, US Department of Health and Human Services</i></p> |
| 16.50-17.20 | <p>Q&A Session 2: Experiences from the civil society</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Sergio Sosa-Estani, Drugs for Neglected Diseases initiative (DNDi) • Dr Su Wang, chairperson, World Hepatitis Summit 2022 Programme Committee; past president, World Hepatitis Alliance, USA |



| | |
|-------------|---|
| 17.20-17.30 | <p>The experience of the Achcu civil organization in Uruguay <i>Victoria Izquierdo, Asociación Comunidad Hepatitis C, Uruguay</i></p> |
| 17.30-17.40 | <p>Building and advocating for a national law for viral hepatitis <i>Maria Eugenia De Feo Moyano, Fundaciòn HCV Sin Fronteras, Argentina</i></p> |
| 17.40-17.50 | <p>ALEH: Project for micro elimination of hepatitis C in dialysis patients <i>Dr Marcelo Silva, Latin American Association for the Study of the Liver (ALEH)</i></p> |
| 17.50-18.00 | <p>Canada's progress toward viral hepatitis elimination 2021 report: Holding governments accountable <i>Sofia Bartlett and Jennifer Van-Gennip, Action Hepatitis Canada, Canada</i></p> |
| 18.00-18.30 | <p>Q&A and closing remarks</p> |



FRIDAY 10 JUNE, 2022

| Time | Outline |
|-------------|--|
| | <p>The Road to Hepatitis B Cure</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Su Wang, chairperson, World Hepatitis Summit 2022 Programme Committee; past president, World Hepatitis Alliance, USA • Professor Harry Janssen, Erasmus University, Rotterdam |
| 11.00-11.10 | <p>Welcome and opening remarks</p> |
| 11.10-11.18 | <p>101 of hepatitis B virology and immunology <i>Dr Thomas Tu, HepBCommunity.org, Australia</i></p> |
| 11.18-11.26 | <p>What are our approaches to hepatitis B cure and how far are we? <i>Dr Kosh Agarwal, Kings College Hospital, UK</i></p> |
| 11.26-11.34 | <p>Engaging the affected community: What people living with hepatitis B really want <i>Chari Cohen, Hepatitis B Foundation, USA</i></p> |
| 11.34-11.40 | <p>The access question: Lessons learned from hepatitis C and other drugs on global access <i>Jessica Burry, Médecins Sans Frontières, Switzerland</i></p> |
| 11.40-11.48 | <p>The regulatory riddle and research partnerships <i>Veronica Miller, Forum for Collaborative Research, USA</i></p> |
| 11.48-11.58 | <p>Q&A</p> |
| 11.58-12.05 | <p>Closing remarks</p> |



| | |
|-------------|--|
| | Professor Harry Janssen, Erasmus University, Rotterdam |
| 12.15-12.45 | <p>Symposium</p> <p>The Road to HCV elimination: Collaborating to break barriers and eliminate HVC in some of the world's most vulnerable communities</p> <p>Brought to you by: AbbVie</p> <p>Moderator: Paul Sutton, International Government Affairs, AbbVie, USA</p> <p>Speakers:</p> <ul style="list-style-type: none"> • Lindsey Hiebert, Director, Coalition for Global Hepatitis Elimination, USA • Cristiana Merendeiro, Project Manager, CRESCER, Portugal |
| 13.00-13.05 | <p>Financing for hepatitis*</p> <ul style="list-style-type: none"> ➤ This session will involve a country-led discussion on different innovative and sustainable financing models and the role of commodities in the financing discussion. ➤ What has proven feasible and not feasible when financing viral hepatitis programmes will be discussed. <p>Chairs:</p> <ul style="list-style-type: none"> • Finn Jarle Rode, EndHep 2030, Switzerland • Jessica Hicks, World Hepatitis Alliance, UK |
| 13.05-13.10 | <p>Welcome and opening remarks</p> |
| 13.10-13.20 | <p>The cost of implementing the Global Health Sector Strategy <i>Daniel Low Beer, WHO, Switzerland</i></p> |
| 13.10-13.20 | <p>Uzbekistan - progress so far and plans for financing hepatitis elimination in the future</p> |



| | |
|-------------|--|
| | <i>Dr Erkin Musabaev, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Uzbekistan</i> |
| 13.20-13.30 | Taraba State - steps to finance their hepatitis programme and opportunities and difficulties faced <i>Arc. Darius Dickson Ishaku. Executive Governor of Taraba State, Nigeria (TBC)</i> |
| 13.30-13.40 | Sudan - steps to finance their hepatitis programme and opportunities and difficulties faced <i>Dr Sara Azhari Hassan Abdulla, Ministry of Health, Sudan</i> |
| 13.40-13.47 | A “social enterprise” approach to financing <i>Ed Booty, Reach52</i> |
| 13.47-13.54 | Reflections: work of CDAF and GPRO in financing for hepatitis <i>Homie Razavi, Center for Disease Analysis Foundation, USA</i> |
| 13.54-14.01 | Reflections: blended financing as an opportunity for hepatitis elimination <i>Greg Garrett, DNDi, Switzerland</i> |
| 14.01-14.25 | Panel discussion and Q&A - ‘What have we learnt and what still needs to happen’ |
| 14.25-14.30 | Closing remarks |
| | <p>The role of good data, surveillance, monitoring and evaluation in elimination</p> <ul style="list-style-type: none"> ➤ The focus of this session is the importance of data, gaps in surveillance and representation, and how a multi-stakeholder effort can lead to better data collection, interpretation and dissemination for a more impactful response ➤ The data tools and approaches that viral hepatitis programmes have effectively used to strengthen the cascade of care and improve decision-making will be discussed. <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Carolyn Wester, CDC, USA • Professor Jeff Lazarus, Barcelona Institute for Global Health (ISGLOBAL), Spain |



| | |
|-------------|---|
| 14.30-14.35 | Welcome and opening remarks |
| 14.35-14.43 | Surveillance for hepatitis: Making the hepatitis country data collection system work better <i>Daniel Low Beer, WHO, Switzerland</i> |
| 14.43-14.51 | Closing the loop: Utilising data tools to effectively reduce loss to follow up <i>Alida Ngwije, CHAI Rwanda, Rwanda</i> |
| 14.51-14.59 | Uptake of hepatitis B and C antiviral treatment before and after national policy changes in China <i>Professor Jing Sun, Peking Union Medical College</i> |
| 14.59-15.30 | Q&A and closing remarks |
| | <p>Covid19: Impact and opportunities*</p> <ul style="list-style-type: none"> ➤ This session will focus on understanding how to maximise the opportunities created by the Covid-19 pandemic ➤ The barriers will be highlighted and we will explore ways to overcome them. <p>Co-Chairs:</p> <ul style="list-style-type: none"> • John Ward, Global Coalition for Hepatitis Elimination, USA • Mohammed Abdulaziz, Africa CDC, Ethiopia |
| 14.30-14.35 | Welcome and opening remarks |
| | Country experience round table |
| 14.35-14.42 | Combined covid-19 vaccination and hepatitis C and HIV screening for high-risk populations in Madrid, Spain <i>Professor Jeff Lazarus, Barcelona Institute for Global Health (ISGLOBAL), Spain and Jorge Valencia La Rosa, Spain</i> |
| 14.42-14.49 | Scaling-up HBV testing and treatment during covid-19: Experience of pilot in central Philippines <i>Eugene Matildo Arbis, WHO Philippines (TBC)</i> |
| | Enhancing inter-island hepatitis C care networks in Hawaii with Project Echo during covid-19 |



| | |
|-------------|--|
| 14.49-14.56 | <i>Dr Dan Saltman, Hawaii Learning Groups, USA</i> |
| 14.56-15.03 | Covid-19 impact and response on hepatitis B virus and hepatitis C virus prevention and care in Japan <i>Md Razeen Ashraf Hussain, Hiroshima University, Japan</i> |
| 15.03-15.10 | Complementarity between community HCV care and health care services in the time of covid-19 <i>Maria Donatelli Klinger, Coalition Plus, France</i> |
| 15.10-15.30 | Q&A and closing remarks |
| | <p>Innovations in technology and service delivery</p> <ul style="list-style-type: none"> ➤ We will look at what new technologies are available and explore how they can help us better reach people living with viral hepatitis in key populations and the general population. ➤ We will explore ways of dismantling barriers to accessing testing and care, including innovations outside the hep space <p>Co-Chairs:</p> <ul style="list-style-type: none"> • Dr Margaret Hellard, Burnet Institute, Australia • Theobald Owusu-Ansah, Hepatitis Foundation of Ghana, World Hepatitis Alliance, AFRO board member (TBC) <p>Welcome</p> <p>Hepatitis C self-testing</p> |
| 14.30-14.35 | Introduction <i>Sonjelle Shilton, FIND, Switzerland</i> |
| 14.35-14.50 | Hepatitis C self-testing: Impact study in Georgia among key populations <i>Dr Ketevan Stvilia, National Center for Disease Control (NCDC), Georgia</i> |
| 14.50-14.57 | Hepatitis C self-testing experiences from Pakistan <i>Dr Aliya Hasnain, Aga Khan University, Pakistan</i> |



| | |
|-------------|---|
| 14.57-15.04 | Hepatitis B and C prevalence and acceptability of the plasma separation card for viral hepatitis <i>Camila Picchio, Barcelona Institute for Global Health (ISGlobal), Spain</i> |
| 15.04-15.11 | Quick Start Hepatitis C Treatment <i>Sunil Solomon, Johns Hopkins Medicine, USA</i> |
| 15.11-15.18 | The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition <i>Professor Peter Vickerman, University of Bristol, UK</i> |
| 15.18-15.30 | Q&A and closing remarks |
| | Lightning talks: Highlighting abstracts of distinction—<i>Delivering innovations to people living with viral hepatitis*</i> |
| | Chair: Jennifer Johnston, CEVHAP, Australia |
| 15.30-15.35 | Welcome |
| 15.35-15.40 | Interventions to improve HCV care for people who inject drugs: A systematic review and meta-analysis <i>Evan Cunningham, Australia</i> |
| 15.40-15.45 | HepBcommunity.Org: A global online forum dedicated to supporting people with hepatitis B <i>Dr Thomas Tu, HepBCommunity.org, Australia</i> |
| 15.45-15.50 | Kindness begets kindness: Pay-it-forward approach to increase HBV and HCV testing uptake among MSM <i>Ye Zhang, Australia</i> |
| 15.50-15.55 | Hepatitis B commodities, pricing and access strategies <i>Capucine Pénicaud, ICE-HBV, Australia and Mila Maistat, Medicines Patent Pool, Switzerland</i> |
| 15.55-16.00 | Equitable access to HCV comprehensive package of services for PWID In Ukraine – Is this a reality? <i>Zahedul Islam, ICF Alliance for Public Health, Ukraine</i> |



| | |
|-------------|--|
| 16.00-16.30 | Q&A and closing remarks |
| | <p>Hep Can't Wait and closing remarks</p> <p>➤ A session reflecting on the human impact of hepatitis, why hepatitis matters and why Hep Can't Wait</p> <p>Co-chairs:</p> <ul style="list-style-type: none"> • Danjuma Adda, World Hepatitis Alliance, Center for Initiative and Development (CFID) and Chagro-Care Trust (CCT), Nigeria • Dr Meg Doherty, WHO, Switzerland |
| 16.35-17.10 | <p>Reflections and discussion from people living with viral hepatitis and the wider community on the World Health Summit 2022 and why Hep Can't Wait</p> <ul style="list-style-type: none"> • Oanh Khuat, Center for Supporting Community Development Initiatives, Vietnam • David Urick, USA • Dr Patricia Vélez Möller, Guatemalan Association of the Liver, World Hepatitis Alliance, PAHO Board Member |
| 17.10-17.15 | <p>Reading of WHS 2022 Statement</p> <p><i>Danjuma Adda, World Hepatitis Alliance, Center for Initiative and Development (CFID) and Chagro-Care Trust (CCT), Nigeria</i></p> |
| 17.15-17.30 | <p>Closing</p> <ul style="list-style-type: none"> • Cary James, World Hepatitis Alliance, UK • Dr Rui Tato Marinho, Portugal • Danjuma Adda, World Hepatitis Alliance, Center for Initiative and Development (CFID) and Chagro-Care Trust (CCT), Nigeria • Dr Meg Doherty, WHO, Switzerland |

Notes:

All sessions are open to all participants



All times are CEST

** Spanish and French interpretation available*

*** Only French interpretation available*

**** Only Spanish interpretation available*

***** This title has been adjusted to provide consistency with WHO documentary practice*